CAMP4 Therapeutics, a clinical-stage biotech developing RNA-based therapies to target genetic diseases, filed on Friday with the SEC to raise up to $75 million in an initial public offering.
The company is developing regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a broad range of genetic diseases. It is developing a proprietary RNA Actuating Platform to identify and characterize the active regulatory elements controlling expressed genes. Once a disease-associated target gene is identified, it plans to apply the platform to identify the controlling regRNA and rapidly generate novel antisense oligonucleotide, or ASO, candidates. CAMP4 Therapeutics is initially focused on metabolic and central nervous system, or CNS, diseases with validated disease biology, which it believes its platform can help address. Its lead candidate, meant to target urea cycle disorders, is undergoing a Phase 1 trial, which it expects reports from in 2025.
The Cambridge, MA-based company was founded in 2015 and plans to list on the Nasdaq under the symbol CAMP. CAMP4 Therapeutics filed confidentially on June 14, 2024. J.P. Morgan, Leerink Partners, Piper Sandler, and William Blair are the joint bookrunners on the deal. No pricing terms were disclosed.
